Ketoconazole
- Generic Name
- Ketoconazole
- Brand Names
- Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA
- Drug Type
- Small Molecule
- Chemical Formula
- C26H28Cl2N4O4
- CAS Number
- 65277-42-1
- Unique Ingredient Identifier
- R9400W927I
- Background
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...
- Indication
Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.
- Associated Conditions
- Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection
- Associated Therapies
- -
Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]
- Conditions
- Interventions
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT00404378
- Locations
- 🇺🇸
GSK Investigational Site, Lenexa, Kansas, United States
Effectiveness of Two Types of Treatment in Restoring Muscle After Hip or Knee Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 40
- Registration Number
- NCT00393848
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Investigating the Regulation of Reproductive Hormones in Adult Men
- Conditions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2015-02-16
- Target Recruit Count
- 175
- Registration Number
- NCT00392457
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Determine the Impact of Multiple Doses of Ketoconazole on Single-Dose Pharmacokinetics of HCV-796
- Conditions
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2009-07-10
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00384917
Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2019-08-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 49
- Registration Number
- NCT00309894
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Veterans Affairs Medical Center - San Francisco, San Francisco, California, United States
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 80
- Registration Number
- NCT00295919
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT00238225
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Manhattan Eye, Ear & Throat Hospital
- Target Recruit Count
- 5
- Registration Number
- NCT00211393
- Locations
- 🇺🇸
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 29
- Registration Number
- NCT00096317
- Locations
- 🇺🇸
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 260
- Registration Number
- NCT00002760
- Locations
- 🇺🇸
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
🇺🇸University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.